ArticleLancet regional health. Americas2026
Dengue seroprevalence and transfusion risk in three regions of viral circulation in Argentina: a cross-sectional study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Blood donor serosurveys and national dengue burden estimates in Argentina.Lancet regional health. Americas · 2026Article
- Dengue surveillance: complementary strategies for national monitoring.Lancet regional health. Americas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Historically, multiple dengue virus (DENV) outbreaks have been recorded in Argentina. Although some regional studies exist, information remains fragmented and predates the two largest epidemics, underscoring the need for updated estimates. This study aimed to determine anti-DENV IgG seroprevalence among blood donors and evaluate the risk of transfusion-transmitted infection. Methods: Two blood donor surveys in three regions of Argentina were conducted in 2023 (N = 3000) and 2025 (N = 2443). Anti-DENV IgG antibodies were detected using a commercial ELISA. In 2023, DENV-RNA was additionally assessed by RT-PCR. Findings: A total of 5443 adult donors were included (median age 37 years (IQR 29-46); 44% women). In 2023, IgG seroprevalence was 693/3000 (23·1%; 95% CI 21·6-24·7), with regional heterogeneity (13·8-42·0%). Donors >56 years had the highest prevalence (31·8%; p = 0·010). Sex differences were significant: 19·7% in women versus 25·9% in men (p < 0·0001). By 2025, seroprevalence reached 516/2443 (50·6%; 95% CI 48·6-52·6), corresponding to ∼10·2 million new infections compared with 575,000 officially reported cases (∼5·6% ascertainment). Estimates varied substantially across provinces, ranging from 24·2% to 78·8%, with the Northwestern region most affected. Age and sex differences were no longer significant. Nucleic acid testing in 2023 identified DENV-RNA in five donors (0·17%), all from Tucumán, where prevalence reached 2·52% (5/198). Interpretation: Rising seroprevalence among blood donors from urban and peri-urban areas of central, northwest, and northeast Argentina suggests expansion of DENV in these regions. Strengthened surveillance, vector control, vaccination strategies, and targeted donor screening are critical to mitigate epidemic impact and transfusion-related complications. Funding: This research received financial support from TAKEDA Argentina S.A. as part of an Investigator-Initiated Study (code: IISR-2024-200504), with Federico Alejandro Di Lello as the grant recipient. Additional support was provided by grant UBACyT N°20020220100115BA from the Universidad de Buenos Aires (UBA), Buenos Aires, Argentina, and by Fundación René Barón. Some reagents for nucleic acid detection were kindly provided by altona Diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.